Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline

Critically ill patients with multiple myeloma will need to wait a lot longer for an experimental new cancer therapy from Bristol Myers Squibb (NYSE:BMY) and bluebird bio (NASDAQ:BLUE) than they had expected. The FDA has refused to file a new biologics license application that would have made idecabtagene vicleucel (ide-cel) available as a treatment for patients who have run out of options.